Long-Acting Implant Shows Promise for Patients with Non-Infectious Uveitis

The study included 11 patients who were randomized to either a low- or high-dose FAi
The study included 11 patients who were randomized to either a low- or high-dose FAi

According to a study published in the journal Ophthalmology an injectable fluocinolone acetonide (FAi) long-acting implant may be able to effectively control intraocular inflammation, as well as improve visual acuity, in patients with a history of recurrent noninfectious intermediate uveitis, posterior uveitis, or panuveitis.

Duke University researchers set out to determine the effect of the implant by conducting a non-comparative, interventional, dose-randomized, dose-masked, prospective, individual, investigator-sponsored investigational new drug study. 

Eleven study patients with a history of recurrent noninfectious intermediate uveitis, posterior, or panuveitis were included in the study. They were randomized to either a low- or high-dose FAi. The 11 eyes were observed on Day 0 (implant injected) and then regularly through 2 years. Main study outcome measures included ocular inflammation, visual acuity, anti-inflammatory medication use, and safety parameters prior to and after implantation. 

Related Articles

Mean study eye visual acuity improved significantly from 0.56 logarithm of the minimum angle of resolution (logMAR) to +0.25 logMAR (P=0.041) at 12 months, and to +0.17 logMAR (P=0.016) at 24 months post-implantation. The average number of inflammation recurrences in the 12 months prior to implantation was 1.54 episodes per eye but none of the study eyes had a recurrence during the follow-up period. 

The dosage was reduced in four of the six study patients who continued receiving systemic medication post-implantation. An average of 1.6 Sub-Tenon triamcinolone acetonide (PSTA) injections were administered to 5 of 11 eyes in the 12 months prior to implantation but no PSTA injections were required after FAi implantation. 

In addition, the most common adverse event was a rise in intraocular pressure (IOP). The elevated IOP was managed by conventional methods. 

Study authors concluded that "it is feasible to place a long-acting FAi in an outpatient setting without prolonged adverse events attributed to the implant injection procedure." The FAi implant may be a promising option for patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis who do not respond to, or are intolerant to, conventional treatment, they added.

For more information visit aaojournal.org.

Loading links....